We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Outcomes for olfactory neuroblastoma treated with induction chemotherapy.
- Authors
Su, Shirley Y.; Bell, Diana; Ferrarotto, Renata; Phan, Jack; Roberts, Dianna; Kupferman, Michael E.; Frank, Steven J.; Fuller, C. David; Gunn, G. Brandon; Kies, Merrill S.; Glisson, Bonnie S.; Hanna, Ehab Y.
- Abstract
Background Oncologic outcomes for induction chemotherapy and its role in patients with advanced olfactory neuroblastoma (ONB) remain unclear. Methods A retrospective review of 15 consecutive patients with extensive local invasion and/or nodal disease treated with induction chemotherapy with curative intent followed by definitive local therapy. Results The majority of patients were treated with cisplatin and etoposide. The response to chemotherapy was 68% (10/15). Response was 78% (7/9) in the high Hyams high-grade group and 50% (3/6) in the Hyams low-grade group. Seven patients had complete response (CR) and 3 patients were able to avoid orbital exenteration. The 5-year disease-free survival (DFS) and overall survival (OS) were 71% and 78%, respectively, with a trend toward improved survival in patients with CR. Conclusion ONB is a chemosensitive tumor and induction chemotherapy is an acceptable strategy for aggressive and locoregional advanced disease. Hyams grade may predict chemosensitivity and CR may be associated with improved survival.
- Subjects
CISPLATIN; NEUROBLASTOMA; ALKYLATING agents; NERVOUS system cancer; PROGRESSION-free survival
- Publication
Head & Neck, 2017, Vol 39, Issue 8, p1671
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.24822